Abstract
α-Emitters show higher cytocidal effects compared with β-emitters because α-emitters can deposit high energy within a short range, whereas the range of β-emitters is longer. Although α-radioimmunotherapy (α-RIT), a therapeutic nuclear medicine with radiolabeled antibodies with α-emitters, has the potential of high therapeutic efficacy; many clinical trials for hematological malignancies have been done, but a few for solid tumors. However, the clinical trials are increasing and four trials with 225Ac and 227Th, which would play a major role in nuclear medicine for solid tumors, started in 2017 or later. Research and development of different α-RIT is conducted over the world. In this section, we first provide an overview of RIT and then focus on α-RIT.
